COMPANY
Xcel Research LLC
Xcel Research LLC: warning letter recipient for Retatrutide, Semaglutide, as stated by public registers.
WARNING LETTER RECIPIENT
Received an FDA warning letter naming the peptide.
| Retatrutide | Unapproved New Drugs/Misbranded, 2024-12-10 Regulator FDA warning letters |
|---|---|
| Semaglutide | Unapproved New Drugs/Misbranded, 2024-12-10 Regulator FDA warning letters |
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.